United Therapeutics CorporationUTHRNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank28
Year-over-Year Change
Year-over-year operating cash flow growth rate
Latest
-38.41%
↓ 257% vs avg
Percentile
P28
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
24.50%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -38.41% |
| Q3 2025 | 193.22% |
| Q2 2025 | -58.43% |
| Q1 2025 | 35.17% |
| Q4 2024 | -9.54% |
| Q3 2024 | 62.45% |
| Q2 2024 | -38.33% |
| Q1 2024 | 149.83% |
| Q4 2023 | -56.47% |
| Q3 2023 | 225.68% |
| Q2 2023 | -71.64% |
| Q1 2023 | 192.36% |
| Q4 2022 | -50.43% |
| Q3 2022 | 103.62% |
| Q2 2022 | -56.01% |
| Q1 2022 | 65.35% |
| Q4 2021 | -5.93% |
| Q3 2021 | 25.24% |
| Q2 2021 | 65.03% |
| Q1 2021 | -28.84% |
| Q4 2020 | -49.70% |
| Q3 2020 | 52.99% |
| Q2 2020 | -23.58% |
| Q1 2020 | 109.37% |
| Q4 2019 | -44.71% |
| Q3 2019 | 39.50% |
| Q2 2019 | 121.18% |
| Q1 2019 | -834.66% |
| Q4 2018 | -64.04% |
| Q3 2018 | 32.09% |
| Q2 2018 | -34.78% |
| Q1 2018 | 421.33% |
| Q4 2017 | -133.19% |
| Q3 2017 | 265.63% |
| Q2 2017 | -69.37% |
| Q1 2017 | 41.25% |
| Q4 2016 | -28.55% |
| Q3 2016 | 81.94% |
| Q2 2016 | -0.08% |
| Q1 2016 | 393.33% |